Cellebrite DI Tidigare resultatutveckling
Tidigare kriterier kontrolleras 3/6
Cellebrite DI s intäkter har minskat med en genomsnittlig årlig takt på -39.1%, medan Software -branschen såg intäkter på växande på 21.4% årligen. Intäkterna har varit växande med en genomsnittlig takt på 17.1% per år. Cellebrite DI s avkastning på eget kapital är 16.2% och den har en nettomarginal på 16.4%.
Viktig information
-39.06%
Tillväxttakt i vinsten
-39.95%
Tillväxttakt för EPS
| Software Tillväxt i branschen | 17.33% |
| Intäkternas tillväxttakt | 17.06% |
| Avkastning på eget kapital | 16.17% |
| Nettomarginal | 16.36% |
| Nästa resultatuppdatering | 14 May 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential
Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential
Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat
Apr 06CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential
Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration
Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power
Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.
CLBT: Higher Profitability Assumptions Will Support Stronger Medium Term Earnings Power
Analysts have raised their price target on Cellebrite DI from US$18.00 to US$23.00, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E as the key drivers of the change. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, with expected revenue between US$123 million and US$128 million and annual growth guidance of 13% to 17% (company guidance).CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power
Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit
Jan 13
CLBT: Sustained Margin Strength Will Support Future Earnings Power
Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead
Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead
Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year
Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You
Sep 09Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 18Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.
Cloud-Ready AI And Inseyets Migration Will Expand Digital Capabilities
Shift to cloud-based AI platforms and expansion in digital investigations are set to boost revenue through subscription services and high-margin solutions.Cellebrite DI: A Compounder But Not Yet Priced For Conviction Buy
Apr 24Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 16Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation
Feb 04A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)
Jan 10Cellebrite: There Are Potential Risks That Could Damper Growth
Nov 08Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?
Oct 30There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased
Sep 10Cellebrite: Rating Downgrade As Valuation Has Caught Up
Aug 27Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up
Aug 17Fördelning av intäkter och kostnader
Hur Cellebrite DI tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Dec 25 | 476 | 78 | 220 | 114 |
| 30 Sep 25 | 456 | 76 | 212 | 110 |
| 30 Jun 25 | 437 | -151 | 197 | 107 |
| 31 Mar 25 | 419 | -194 | 190 | 102 |
| 31 Dec 24 | 401 | -283 | 183 | 98 |
| 30 Sep 24 | 385 | -317 | 175 | 95 |
| 30 Jun 24 | 362 | -103 | 166 | 89 |
| 31 Mar 24 | 343 | -112 | 161 | 86 |
| 31 Dec 23 | 325 | -81 | 154 | 84 |
| 30 Sep 23 | 306 | -64 | 145 | 82 |
| 30 Jun 23 | 294 | -42 | 145 | 84 |
| 31 Mar 23 | 280 | 20 | 142 | 82 |
| 31 Dec 22 | 271 | 116 | 138 | 81 |
| 30 Sep 22 | 265 | 165 | 138 | 80 |
| 30 Jun 22 | 259 | 152 | 142 | 75 |
| 31 Mar 22 | 255 | 122 | 132 | 70 |
| 31 Dec 21 | 246 | 70 | 124 | 66 |
| 30 Sep 21 | 236 | 7 | 118 | 61 |
| 30 Jun 21 | 223 | 7 | 98 | 58 |
| 31 Mar 21 | 209 | 2 | 96 | 56 |
| 31 Dec 20 | 195 | -9 | 92 | 54 |
| 31 Dec 19 | 172 | -10 | 91 | 47 |
Kvalitetsintäkter: CLBT har inkomster av hög kvalitet.
Växande vinstmarginal: CLBT blev lönsam tidigare.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: CLBT har blivit lönsamt under de senaste 5 åren och ökat intäkterna med -39.1% per år.
Accelererande tillväxt: CLBT har blivit lönsamt under det senaste året, vilket gör det svårt att jämföra vinsttillväxttakten med 5-årsgenomsnittet.
Resultat vs industri: CLBT har blivit lönsamt under det senaste året, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Software branschen ( 16% ).
Avkastning på eget kapital
Hög ROE: CLBT s avkastning på eget kapital ( 16.2% ) anses vara låg.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/04/29 09:52 |
| Aktiekurs vid dagens slut | 2026/04/29 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cellebrite DI Ltd. bevakas av 9 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Tyler Radke | Citigroup Inc |
| Jeffrey Van Rhee | Craig-Hallum Capital Group LLC |
| Bhavin Shah | Deutsche Bank |